Sounds Locked to ElectroEncephalogram Phase For the Acceleration of Sleep Onset Time

NCT ID: NCT05743114

Last Updated: 2024-02-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-02-02

Study Completion Date

2024-01-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study seeks to test whether auditory stimulation delivered at specific phases of the alpha oscillation (as measured by electroencephalogram) can accelerate sleep onset.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In healthy sleepers, cortical alpha oscillations are present during the transition from wakefulness to sleep, and dissipate at sleep onset. For individuals with insomnia, alpha power is elevated during the wake-sleep transition and can persist throughout the night. This study tests whether a wearable device that delivers auditory stimulation phase-locked to alpha oscillations can accelerate sleep onset in healthy adults who report difficulties falling and staying asleep. The device is a prototype of the Elemind Neuromodulation system (ENMod). The ENMod is a wireless headband that measures brain signals, computes the phase of neural oscillations in specific frequency bands, and delivers audible pink noise pulses at specific times relative to the instantaneous phase of neural oscillations. In this study, we ask participants to wear the ENMod headband at home while going to sleep. The device is programmed to record EEG activity and, during the transition from wakefulness to sleep, deliver phase-locked sounds that are intended to interact with the participants neural activity and accelerate sleep onset.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Sleep Disturbance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors
Conditions are blinded to the participant and during data analysis and sleep scoring

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sleep Onset Latency Crossover

Arm 1 is a crossover arm in which participants receive one block of active stimulation (experimental) and a second block in which the device is worn and actively recording, but not delivering phase-locked auditory stimulation (sham). The order of blocks is randomized for each participant.

Group Type EXPERIMENTAL

Elemind Neuromodulation (ENMod)

Intervention Type DEVICE

The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.

Wake After Sleep Onset

This arm tests active stimulation during sleep onset, as well as additional stimulation if participants wake up during the night. One of 4 possible conditions are randomized for each stimulation even (within subject and within nights): Stimulation locked to alpha peak phase, stimulation locked to alpha trough phase, white noise (active sham), and no sound (control).

Group Type EXPERIMENTAL

Elemind Neuromodulation (ENMod)

Intervention Type DEVICE

The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Elemind Neuromodulation (ENMod)

The ENMod is a headband that measures electroencephalogram (EEG) activity, computes the phase of neural oscillations in real-time, and delivers auditory pulses intended to interact with ongoing neural oscillations.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to provide informed consent after reading and answering questions in written English
* Self-report that it takes 30 minutes on average or more to fall asleep
* Subthreshold to Moderately severe Clinical insomnia symptoms (ISI \< 21)
* Subthreshold to Moderately severe Clinical insomnia (PSQI \> 6)
* Minimal risk for severe Generalized Anxiety Disorder (GAD-7 \< 15)
* Minimal risk for severe Generalized Anxiety Disorder (GAD-7 \< 15)
* Individuals that are not actively being treated for anxiety, insomnia, ADHD or other psychological disorders with medications
* Self-report of difficulty staying asleep "Moderate," "Severe," or "Very Severe"
* Self report of waking up in the middle of the night/early morning one or more times per week

Exclusion Criteria

* Unable to read or understand English
* Body Mass Index (weight/height ratio) \>33
* Self-report of being diagnosed with apnea
* Current or past history of a neurological disorder or psychiatric illness
* Self-report that it takes less than 30 minutes to fall asleep on average
* Severe Clinical insomnia symptoms (ISI \> 21)
* Good sleepers (PSQI \< 6)
* High risk for severe Generalized Anxiety Disorder (GAD-7 \> 15)
* Moderate to high risk for alcohol abuse disorder (AUDIT \>6)
* individuals that are actively being treated for anxiety, insomnia, ADHD or other psychological disorders with medications
* Consumption of more than 4 cups of Caffeinated beverages per day
* Any caffeine \< 6hrs prior to each recording session (e.g. coffee, tea, caffeinated sodas etc.)
* Any seizures or family history of seizures
* History of migraine
* History of brain related injury or unexplained loss of consciousness
* Cardiac pacemaker or intracranial metal implant
* Pregnant
* Taking any anti-depressants, stimulants, medication for hypertension or hypotension and/or cannabis derived products
* Cochlear implant in either ear
* Diagnosed with hearing impairment or deafness
* Works night shifts any night of the week
Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Elemind Technologies, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Elemind Technologies, Inc

Cambridge, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Bressler S, Neely R, Yost RM, Wang D. A randomized controlled trial of alpha phase-locked auditory stimulation to treat symptoms of sleep onset insomnia. Sci Rep. 2024 Jun 6;14(1):13039. doi: 10.1038/s41598-024-63385-1.

Reference Type DERIVED
PMID: 38844793 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-02-13

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Earbud EEG Feasibility Study
NCT05257811 COMPLETED
tFUS to Enhance Alertness and Performance
NCT06461221 WITHDRAWN EARLY_PHASE1
Human Intracranial Electrophysiology
NCT05529264 RECRUITING NA